Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
about
An in vivo method to quantify lymphangiogenesis in zebrafishTuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth.Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.Netrin-4 induces lymphangiogenesis in vivoMembrane proteomic analysis of pancreatic cancer cells.Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis.Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis.Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer.Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental modelsPhase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.Roles of the immune system in skin cancer.Review series: TOR kinase complexes and cell migration.Autophagy activation by rapamycin reduces severity of experimental osteoarthritis.Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive.Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.mTOR signaling in cancer cell motility and tumor metastasis.Role of mTOR signaling in tumor cell motility, invasion and metastasisOverlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.Lymphangiogenic factors, mechanisms, and applications.The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer.Induction of cytokines and growth factors by rapamycin in the microenvironment of brain metastases of lung cancer.Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy.Cutaneous Toxicities From Transplantation-Related Medications.Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma.Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro.A transplant patient with a swollen legRole of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Bone fracture in a rat femoral fracture model is associated with the activation of autophagy.Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.Rapamycin-induced autophagy activity promotes bone fracture healing in rats.Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone.
P2860
Q28483763-DA0DD17A-552C-4A12-A5FB-EF3C5D055B4EQ30248734-43FC3E18-C4DB-453C-9EFC-B1113A1F2EEEQ33412904-33E6A131-1FC2-406A-9BEF-ED73AF71340BQ33905175-56423A89-E51D-4EF4-97E2-67953BB57A58Q33985154-75B80199-FAEB-43C4-917B-4D1E42D25CE5Q34173879-F811118D-D5CE-4B90-92E9-FC9CCFE4FCD6Q34321539-2E455D46-E46A-476D-9524-47252D121C7BQ34326240-2DD5999E-50F0-4068-8D8B-A4F5A4CBD283Q34558856-F1D5FEFB-BA9F-43BA-934B-CEEFD4D43547Q34788361-0B2052F7-3C43-4EB5-B750-1EF930AB2051Q35142268-8292807F-2745-4731-BDCC-286C77AEA19FQ35174365-98720155-F503-4694-A24E-827A91303A8BQ35196528-4000DE6F-4742-4FE7-B5F1-3A3EE624E4F3Q35403714-87052F6C-CA6E-4016-ACA3-AAEF196CE573Q35579442-9C98C295-AECE-4010-95C2-B60DBD1824C9Q35803625-888B6D0A-01C7-4F9D-BEBE-83E815E0E32FQ35882208-3DCE44C7-8D98-4E6B-862F-D7F54E99516FQ35947903-84100EF3-6053-4E39-9682-2A148494FA51Q36171949-B9F56BF6-D468-4C90-A2C5-9ED19C966F99Q37047634-304196DE-A3E0-4AA2-B484-B61CA0A48CE4Q37156639-D779AE2E-C8C6-4075-9EA5-A74770416174Q37374986-48C2128C-C32D-4E17-B593-CE04A691BE43Q37448103-34F94077-B125-4FD6-A636-1AD098C84467Q37763231-E1CD72AC-858C-46B8-AC5D-CB649D260FDEQ37824477-3E72F4BE-6202-455C-A3BD-7AC7F7A6793FQ38026529-75B3A6BC-A232-4B74-BE5C-A2EE34BE29E3Q38192927-FE44105D-8CB0-4C18-A74A-515CA2140247Q38829846-BA17274D-73B4-42DD-AA3C-8F3899412FF8Q39191393-D9C8963F-A9DA-4B85-86AA-0566F4474F4DQ39205923-5D225288-A4E6-4B84-9E35-EA345352F0E0Q39269082-CE2C6E05-C508-4C40-BB2F-15F6DD0A436BQ39516781-1BE29B46-80F3-4324-9B1C-88BCB5BD227DQ39701679-41F3743F-C165-4245-AA29-F16760884A47Q40684724-7FE87EDB-A27A-42AA-A19B-671B917DCC79Q41814495-77EABF57-3112-4BAF-9A7D-D1ADCFB5CF6FQ41970819-96D93F82-1EAC-4E53-AA3F-0C19757CFD23Q42236334-0E8EC6AD-1F44-4B65-A6CD-7DC90E823E63Q42272472-4963AFD5-86AB-4EE0-9B65-A2FB4CAF429BQ43244262-22F64CAD-D18C-4ABE-9C6D-2722DBC069A6Q44729102-AEBC4E2C-9C39-4D7F-BF6A-70964F08C336
P2860
Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rapamycin, a specific inhibito ...... esis and lymphatic metastasis.
@en
type
label
Rapamycin, a specific inhibito ...... esis and lymphatic metastasis.
@en
prefLabel
Rapamycin, a specific inhibito ...... esis and lymphatic metastasis.
@en
P2093
P2860
P1433
P1476
Rapamycin, a specific inhibito ...... esis and lymphatic metastasis.
@en
P2093
Hiroshi Ishikura
Masaru Miyazaki
Masayuki Otsuka
Shigeyuki Kamata
Soichi Kobayashi
Takashi Kishimoto
P2860
P304
P356
10.1111/J.1349-7006.2007.00439.X
P577
2007-05-01T00:00:00Z